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Recent advances in the m.anagem.ent ofacute leukaem.ia in adults
A cancer control programme for South Africa
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should be monitored. There was acknowledgement that
there is at present no coherent national policy on
primary cancer prevention, and no linkage of all the
organisations concerned with cancer prevention or
management into a national network. TO national
priorities have been set, and no consensus has been
reached on those conditions that mayor may not be
preventable or detectable at an early stage.
The purpose of the NCCP would be to initiate, co-
ordinate and monitor cancer control activity across the
country, to liaise with government and other interested
parties, and to consolidate fund-raising campaigns. The
TCCP would work towards the reduction of lifestyle risk
factors (tobacco smoking, alcohol abuse, bad dietary
practices, excessive sunlight exposure, risky sexual
behaviour, etc.) and environmental factors (occupational
exposure, air pollution, radiation, water pollution and
food contaminants) known or suspected to cause cancer.
Thus, the NCCP would support a ban on advertising
cigarenes, sponsor education of the youth on smoking,
and lobby against the subsidisation of tobacco farmers.
The NCCP would pursue health promotion in a holistic
manner, and in accordance with the Onawa Charter.
The TCCP would be drawn from CN SA and from
those organisations with an interest in the prevention,
detection, research and treatment of cancer. It would
maintain an office initially at CANSA, and would be
headed by a 'Cancer Tzar' funded by the Department of
Health, but independent from it. The NCCP would be
subject to ongoing monitoring and periodic review, and
its effectiveness measured in the light of ational
Cancer Registry data, and in terms of the outcomes of
specific projects. The NCCP would be the clearing
house for all cancer programmes in South Africa, and
would be responsible for co-operation with international
organisations such as the WHO.
It was generally recognised that to put together a
coherent national cancer policy and establish an NCCP
there would be a need to cultivate political will and
commitment. To this end, the proposals regarding the
NCCP were to be presented to the National Health
Forum as well as to the health minister of the new
government. There was a strong commitment of sup-
port and assistance from the WHO representative. The
SAMJ congratulates and supports CANSA in this initia-
tive, and hopes that the plans mooted in Midrand are
beginning to take shape.
represents a significant advance compared with the dis-
mal prognosis associated with acute leukaemia a few
decades ago.
Such substantial progress has resulted from improve-
ments in the understanding of the biology of the disease,
the development of newer diagnostic techniques which
allow more accurate definition of prognostic factors,
improved supportive care, the discovery and develop-
ment of more effective chemotherapeutic agents
(including differentiating agents and biological response
modifiers) and, more importantly, the rational use of
these and existing therapies, as well as the wider applica-
tions of bone marrow transplantation as an effective
post-remission strategy. All these factors have contri-
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I n September 1993 the Cancer Association of SouthAfrica (CANSA), under the able leadership ofProfessor Frans Geldenhuys, convened a landmark
3-day Cancer Control Workshop in Midrand with inter-
national participation, to consider the establishment of a
national cancer control programme for South Africa
according to the policies and guidelines laid down by
the World Health Organisation. With representatives
from the medical schools, the Medical Research
Council, the South African Institute for Medical
Research, the late Department of Tational Health and
Population Development, the provincial administra-
tions, the hospice movement, a variety of non-govern-
ment organisations and several other instances, the
workshop was arguably the largest indaba ever convened
on the subject of cancer prevention in South Africa. Of
special significance was the anendance at the workshop
by Professor Jan Stjernswiird, the Swedish-born WHO
representative and cancer expert; Ms Jeanene Webber
of the McMillan Cancer Relief Trust in the UK; and Dr
Gustav Wolvaardt of the South African Permanent
Mission to the WHO. Dr Derek Yach served as the pro-
ceedings recorder.
The workshop first reviewed the existing cancer
situation in South Africa: the epidemiology of cancers
prevalent in this country; lifestyle and environmental
risk factors; organisations and other resources available
for the campaign against cancer; possible means of can-
cer prevention, education and early detection and so on.
The workshop then identified cervical, skin, breast and
lung cancers as the most targetable malignancies in
South Africa in terms inter alia of the magnitude of the
problem; preventability and/or early detectability; and
ready access to and efficacy of early therapeutic inter-
vention. Cervical carcinoma provides a good example of
targetability: more women die of cervical cancer than
men and women combined who die of AIDS in the
world each year, yet cervical cancer is preventable, can
be detected early and can be treated successfully. Six
other cancers (oesophagus, liver, prostate, large bowel,
lymphoma and mesothelioma), whose early detection
and preventability remain unclear or controversial, were
recommended for funher research to determine whether
they should receive priority in a national cancer preven-
tion scheme.
The workshop then looked into the feasibility of a
national cancer control programme (NCCP) for South
Africa: why we need it, what its goals and objectives
should be, who should be involved and how its impact
Striking progress and advances in the managementof acute leukaemia have occurred in the last2 - 3 decades. I,' Prior to this period, acute leukae-
mia was generally regarded as an incurable disease.
Today, appropriate therapy allows 65 - 90% of
patients with acute lymphoblastic leukaemia (ALL)
and 50 - 80% of patients with acute myeloid leukaemia
(AML) to achieve complete remission. Prolonged dis-
ease-free survival without recurrence of disease (tanta-
mount to cure) is possible in approximately one-third
of adults with ALL and 10% of patients with AML.
This is particularly true of younger adults with
favourable prognostic factors. Although higher cure
rates are the goal for the future, the present situation
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buted to the improved cure rates observed in acute
leukaemia.
Management of patients with acute leukaemia should
be initiated promptly, at a specialised centre, by an inte-
grated, multidisciplinary health care team. The two
principal arms of treaunent are supportive measures and
specific therapy. Supportive measures are primarily
aimed at prevention and management of the haemo-
rrhagic and infective complications of the severe myelo-
suppression associated with therapy or disease.
Improvements in blood component therapy (especially
the availability of platelet concentrates), use of broad-
spectrum antimicrobial agents, specialised nursing care,
antiseptic measures and the recent introduction of
haematopoietic growth factors have all contributed to
the decline in morbidity and mortality that accompany
bleeding and infection. Use of haematopoietic growth
factors such as granulocyte-macrophage colony-stimu-
lating factor (GM-CSF) and granulocyte colony-stimu-
lating factor (G-CSF) is associated with accelerated
neutrophil recovery, shorter period of neutropenia and
reduction in the frequency of infection and the need for
intravenous antibiotics.3 These agents also allow for
more intensive therapy to be administered in a safe
manner.4 •5 Other aspects of the overall management of
the patient (e.g. psychosocial, nutritional) should not be
overlooked.
Specific therapy is conveniently divided into two
phases: remission induction therapy and postremission
therapy. The gold standard in remission induction
therapy in AML involves a combination of cytosine
arabinoside and daunorubicin, with or without thiogua-
nine. A complete remission rate of 60 - 75% is possible
with this regimen.· Various approaches have been
employed in order to improve the remission rate or
extend the remission duration. These entail increasing
the dose or duration of Cytotoxic therapy (e.g. Cytosine
arabinoside), substitution of existing drugs by newer or
equivalent agents (e.g. daunorubicin by idarubicin or
mitoxantrone) or the addition of other agents (e.g.
etoposide) to the standard regimen. '·10 More recently
high-dose, short-course chemotherapy has been used
(e.g. high-dose cytosine arabinoside and high-dose
mitoxantrone, with or without etoposide) in an anempt
to improve the 'quality' of remission." Whether such
intensive therapy is associated with acceptable toxicity
and whether a bener 'quality' remission will translate
into higher overall cure rates is currently unknown, and
is the subject of ongoing trials.
The primary goal of therapy in ALL is cure.
Although this can be realised in 60 - 70% of children,
the outlook in adults is less favourable. Approximately
one-third of adutls achieve long-te= cure. Complete
remission rates of 65 - 90% are possible with ALL
remission induction therapy, using prednisone, vin-
cristine and an anthracycline. 12 The addition of L-
asparaginase to the above three-drug combination does
not affect the remission rate, but improves remission
quality. The outcome in certain ALL subgroups has
improved with the inclusion of cyclophosphamide and
cytosine arabinoside for T -AlL, and high-dose metho-
trexate for B_ALL. I3-15 More intensive therapies employ-
ing high-dose cytosine arabinoside, high-dose metho-
trexate, etoposide and anthracyclines have resulted in
prolongation of remission and increases in disease-free
survival rates, as well as a decrease in the proportion of
patients with resistant disease. I.
Once remission is anained, further therapy is neces-
sary to eradicate subclinical residual disease and prevent
relapse. Postremission therapy has resulted in prolonga-
tion of remission duration compared with no therapy at
all. More effective therapy during this phase is likely to
have a major impact on long-term survival. Current
therapeutic approaches include chemotherapy and bone
marrow transplantation.
In AML, more intensive chemotherapy (high-dose,
short-duration chemotherapy referred to as intensifica-
tion and administered for 1 - 3 cycles) is a current trend
that is now being favoured in preference to consolida-
tion and maintenance therapy. Recent studies have
demonstrated no survival advantage with maintenance
treatment, and prolongation of remission duration is
probably a measure of early postremission therapy
rather than continued maintenance.",I. It is useful to
stratifY patients into low- and high-risk categories based
on the presence of adverse prognostic factors, so that a
risk-directed approach may be employed where possible.
In low-risk patients (de novo AML, young age group)
the probability of disease-free survival 3 or more years
after bone marrow transplantation does not differ signi-
ficantly from the results obtained with intensive post-
remission chemotherapy. In such patients, allogeneic
bone marrow transplantation should be delayed until
documentation of early first relapse. In high:-risk patients
(secondary AML, adverse cytogenetic abnormalities,
etc.) under the age of 55 years, who have a high proba-
bility of relapse, bone marrow transplantation should be
considered in first remission. It should also be consid-
ered in relapsed and refractory AML. Allogeneic bone
marrow transplantation is still regarded as the most
definitive (curative) therapy in AML because of the low
rate of relapse. However, it is only feasible in 10 - 20%
of patients. As a consequence of this, the scope has
broadened to include autologous bone marrow trans-
plantation and, as an alternative to marrow stem cells,
the use of peripheral blood stem cell rescue following
marrow ablation from high-dose chemotherapy.I~21The
precise role of these laner approaches is likely to become
clear in the near future.
Age is a major adverse prognostic factor in AML,
with elderly patients generally achieving a lower remis-
sion rate and shorter survival. In most series, elderly
patients (>60 years) account for more than a third of the
total number, and therefore constitute a large group of
patients. Therapeutic options in the elderly are still
unclear and pose a major challenge. Some of the thera-
pies advocated include use of conventional chemothera-
peutic regimens, shortening the duration and anenuat-
ing the dose of therapy, substitution of daunorubicin by
other aniliracyclines (e.g. idarubicin or mitoxantrone),
and the use of low-dose chemotherapy and palliation.22,23
In ALL likewise, more intensive therapy is favoured
in the postremission phase, especially in high-risk
groups, as this may nullify some of the poor prognostic
factors and'enhance long-term survival.I.,2' Unlike AML,
central nervous system prophylaxis and maintenance are
established forms of therapy in ALL. The benefit of
maintenance therapy appears to be greater in low-risk
patients than in high-risk groups (e.g. Philadelphia (Ph')
positive and B-AlL). In such individuals, short inten-
sive protocols may be more appropriate, with early
recourse to bone marrow transplantation (i.e. in first
remission).25,2. An alternative approach in Ph'-positive
AlL entails the use of a-interferon in an anempt to
maintain remission. 27 Bone marrow transplantation
should also be considered in relapsed and refractory
AlL.
o current review of acute leukaemia is complete
without mention of acute promyelocytic leukaemia
(APL), a subtype of AML with distinctive clinical, mor-
phological and biological features. The disease is charac-
terised by a bleeding diathesis (disseminated intravascu-
lar coagulopathy), a balanced translocation involving
chromosomes 15 and 17 and leading to fusion between
two nuclear transcription factors, viz. PML (promyelo-
cytic leukaemia) from chromosome 15 and RARa
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(retinoic acid receptor alpha) on chromosome 17. This
results in two fusion genes, PML\RARa and RARa\
PML. The former fusion protein is thought to be
responsible for the differentiation block of the leukaemic
blasts at the promyelocyte stage and the striking efficacy
of retinoic acid to the differentiating activity.2S·}O Com-
plete remission rates of 50 - 80% are possible in APL
with conventional chemotherapy and improved support-
ive care. Mortality resulting primarily from haemorrhage
is a major problem in the remission induction period.
Use of rerinoic acid in the induction phase results in
rapid improvement in the coagulation defect, a decrease
in mortality and a higher remission rate. Once remission
is achieved, survival is often longer compared with other
AML subtypes. 31 Long-term therapy with retinoic acid is
associated with relapse and resistance to subsequent
treatment as well as a number of potential side-effects.
Currently, retinoic acid is recommended for remission
induction only. Combination chemotherapy should be
administered in the postremission phase.'9-" The role of
cylokines and alternative retinoids is currently being
investigated.
Research in APL has provided new insights into
leukaemogenesis. Having defined the molecular lesion it
is now possible to target appropriate therapy at the
defect, and to utilise the molecular defect as an indicator
of residual disease. The discovery of sensitive methods
to detect minimal residual disease (e.g. in situ hybridisa-
tion, polymerase chain reaction) represents a major
advance, as this allows assessment of the effectiveness of
therapy and assists in planning future therapy. Further
progress in acute leukaemia will depend on the effective-
ness of early intensive therapy in improving the cure
rate, greater application of the haematopoietic growth
factors and biological response modifiers such as a-
interferon and the interleukins, e.g. IL-2, IL-4 and IL-7,
and devising better methods of circumventing or over-
coming multidrug resistance, which is an important
cause of treatment failure.
In the local context, what is required is a flexible and
rational approach in the management of acute leukae-
mia. Careful consideration of individual risk factors in
the context of the available resources is necessary, in
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